OverviewSuggest Edit

Medivir researches, develops, and sells pharmaceuticals primarily for the treatment of oncology. The Company's products portfolio includes Remetinostat for use in the treatment of cutaneous T-cell lymphoma; Birinapant in combination with Keytrudafor treating solid tumors; and MIV-711 for the treatment of osteoarthritis, as well as MIV-818, a preclinical stage nucleoside pro-drug for treating patients with advanced liver cancers. Its products also include drugs for the treatment of labial herpes and hepatitis C virus.

TypePublic
Founded1988
HQHuddinge, SE
Websitemedivir.com

Latest Updates

Employees (est.) (Sept 2020)10(-23%)
Share Price (Oct 2020)KR13.7 (-2%)
Cybersecurity ratingAMore

Key People/Management at Medivir

Linda Basse

Linda Basse

Chief Medical Officer

Medivir Office Locations

Medivir has an office in Huddinge
Huddinge, SE (HQ)
Box 1086 Lunastigen 7
Show all (1)

Medivir Financials and Metrics

Medivir Revenue

Market capitalization (21-Oct-2020)

325.5m

Closing stock price (21-Oct-2020)

13.7
Medivir's current market capitalization is kr325.5 m.
Show all financial metrics

Medivir Cybersecurity Score

Cybersecurity ratingPremium dataset

A

92/100

SecurityScorecard logo

Medivir Online and Social Media Presence

Embed Graph

Medivir News and Updates

Medivir appoints Dr. Tom Morris as interim Chief Medical Officer

STOCKHOLM, Oct. 5, 2020 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) announced today it has appointed Dr. Tom Morris as interim Chief Medical Officer effective October 5, 2020. Dr. Morris will report to CEO Yilmaz Mahshid and join the Medivir Executive Team. Tom Morris has more...

Medivir AB - Interim Report January - June 2020

HUDDINGE, Sweden, Aug. 20, 2020 /PRNewswire/ -- April - June Significant events during the quarter Following the positive opinion given by the European Medicines Agency (EMA), the European Commission granted orphan medicinal product designation in the EU for MIV-818 for the treatment of...

Yilmaz Mahshid takes office as CEO of Medivir on 14 September

STOCKHOLM, Aug. 18, 2020 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) announced today that Dr. Yilmaz Mahshid will assume his position as CEO on September 14, 2020. Uli Hacksell, who has been CEO since October 2018, will remain as a Board Member of Medivir. Yilmaz Mahshid joins...

Medivir and SciLifeLab Enter Collaboration on Potential SARS CoV-2 Inhibitors

STOCKHOLM, July 6, 2020 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announced that it has entered a research collaboration with the Drug Discovery and Development Platform (DDD) at SciLifeLab on potential inhibitors of SARS CoV-2. Through the collaboration, DDD will get...

Medivir Appoints Yilmaz Mahshid as New CEO

STOCKHOLM, May 26, 2020 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announced that its Board of Directors has appointed Yilmaz Mahshid as the new CEO of the company. Yilmaz Mahshid has long and broad experience from qualified roles in the life science sector. He succeeds Uli...

Medivir and Tango Therapeutics Sign License Agreement for Preclinical Asset

STOCKHOLM, March 16, 2020 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announced that it has entered into a license agreement with US biotech company Tango Therapeutics for one of Medivir's preclinical research programs. Under the terms of the agreement, Medivir will receive...
Show more

Medivir Frequently Asked Questions

  • When was Medivir founded?

    Medivir was founded in 1988.

  • Who are Medivir key executives?

    Medivir's key executives are Linda Basse.

  • How many employees does Medivir have?

    Medivir has 10 employees.

  • Who are Medivir competitors?

    Competitors of Medivir include Joint Academy, Shanghai Henlius Biotech and ImmunoCellular Therapeutics.

  • Where is Medivir headquarters?

    Medivir headquarters is located at Box 1086 Lunastigen 7, Huddinge.

  • Where are Medivir offices?

    Medivir has an office in Huddinge.

  • How many offices does Medivir have?

    Medivir has 1 office.